Mucke Hermann A M
HM Pharma Consultancy, Vienna, Austria.
Vasc Health Risk Manag. 2011;7:265-72. doi: 10.2147/VHRM.S14454. Epub 2011 Apr 18.
This investigation identifies patent applications published under the international Patent Convention Treaty between July 2010 and January 2011 in three significant fields of vascular risk management (arterial hypertension, atherosclerosis, and aneurysms) and investigates whether the inventors have also published peer reviewed papers directly describing their claimed invention.
Out of only 48 patent documents that specifically addressed at least one of the above-mentioned fields, 15 had immediate companion papers of which 13 were published earlier than the corresponding patent applications; the majority of these papers were published by noncorporate patentees. Although the majority of patent applications (30 documents) had at least one corporate assignee, 18 came from academic environments. As expected, medical devices dominated in the aneurysm segment while pharmacology dominated hypertension and atherosclerosis.
Although information related to hypertension, atherosclerosis, or aneurysms that was claimed in international patent applications reached the public quicker through the corresponding peer review document if one was published, more than two-thirds of the patent applications had no such companion paper in a scientific journal. The patent literature, which is freely available online as full text, offers information to scientists and developers in the fields of vascular risk management that is not available from the peer reviewed literature.
本调查确定了2010年7月至2011年1月期间根据国际专利公约条约公布的、涉及血管风险管理三个重要领域(动脉高血压、动脉粥样硬化和动脉瘤)的专利申请,并调查了发明人是否还发表了直接描述其主张发明的同行评审论文。
在仅有的48份专门涉及上述至少一个领域的专利文件中,15份有即时配套论文,其中13份比相应的专利申请发表得更早;这些论文大多由非企业专利权人发表。虽然大多数专利申请(30份文件)至少有一个企业受让人,但18份来自学术环境。不出所料,医疗器械在动脉瘤领域占主导地位,而药理学在高血压和动脉粥样硬化领域占主导地位。
虽然如果发表了相应的同行评审文件,国际专利申请中主张的与高血压、动脉粥样硬化或动脉瘤相关的信息会更快地为公众所知,但超过三分之二的专利申请在科学期刊上没有这样的配套论文。可在网上免费获取全文的专利文献,为血管风险管理领域的科学家和开发者提供了同行评审文献中没有的信息。